HomeGLUE • NASDAQ
add
Monte Rosa Therapeutics Inc
Previous close
$16.48
Year range
$3.50 - $19.17
Market cap
1.07B USD
Avg Volume
1.13M
P/E ratio
65.78
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Revenue | 12.77M | 38.54% |
Operating expense | 11.09M | 8.48% |
Net income | -27.08M | -13.50% |
Net profit margin | -212.10 | 18.07% |
Earnings per share | -0.33 | -13.79% |
EBITDA | -30.88M | -26.43% |
Effective tax rate | 10.50% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 391.26M | 61.55% |
Total assets | 459.84M | 45.94% |
Total liabilities | 214.00M | 95.22% |
Total equity | 245.84M | — |
Shares outstanding | 65.12M | — |
Price to book | 4.14 | — |
Return on assets | -20.12% | — |
Return on capital | -27.70% | — |
Cash Flow
Net change in cash
| (USD) | Sep 2025info | Y/Y change |
|---|---|---|
Net income | -27.08M | -13.50% |
Cash from operations | 100.43M | 578.37% |
Cash from investing | 38.14M | 1.03% |
Cash from financing | 348.00K | 2,220.00% |
Net change in cash | 138.91M | 728.35% |
Free cash flow | 3.59M | 184.96% |
About
Founded
2019
Headquarters
Website
Employees
147
